|
||
|
Venture capital firms and funds in Europe 128 Venture Capital Group 3i Venture Capital Accuitive Medical Acer Venture Capital Act Venture Capital Ltd Adelaide Venture Capital Email ADS Ventures Boston Advantages Of Venture Capital Advent Venture Capital Agio Capital Alabama Venture Capital Alaska Venture Capital All Stages Venture Capital American Venture Capital Analysis Venture Capital Analyze Venture Capital Angel Capital Appraisal Venture Capital Arch Venture Capital Argentina Venture Capital Arizona Venture Capital Arkansas Venture Capital Arrowpath Venture Capital Assess Venture Capital Assessment Venture Capital Atlas Venture Capital ATV Venture Capital Aurora Fund Australia Venture Capital Austria Venture Capital Automotive Venture Capital AZ Venture Capital VCgate More Venture Capital Terms and Topics
-
KaloBios Raises $20 Million in Series C Financing
July 25th, 2007 No comments
KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, recently announced the completion of a Series C venture financing of $20 million. Lehman Brothers led the round, which also included the participation of previous investors MPM Capital, Sofinnova Ventures, Alloy Ventures, GBS Venture Partners, 5AM Ventures, Singapore Bioinnovations Pte., and Lotus BioScience Ventures. Proceeds from the financing will be used to advance clinical development of the company’s two therapeutic antibody candidates, KB001 and KB002.
“We are very pleased to complete this significant financing,” said David Pritchard, the company’s chief executive officer, “which in addition to the major Humaneering™ partnership that we announced in April 2007, further extends KaloBios’ financial resources into 2009. We expect these new funds to support the development of our two lead product candidates, KB001 and KB002 into Phase 2 development, as well as the advancement of a third therapeutic program into clinical trials.”
KaloBios has an ongoing clinical program for KB002 in rheumatoid arthritis. The company also recently initiated Phase 1 studies of KB001, which will be investigated for the treatment of Pseudomonas aeruginosa infections.
“We were attracted to the KaloBios investment opportunity by the combination of the antibody technology platform, the two attractive programs in the clinic, and the experienced management team,” said Jeffrey Ferrell, Senior Vice President of Lehman Brothers. “Given the high demand for antibody programs and technologies in the partnering and merger and acquisition markets, we think KaloBios is well positioned.”
About KaloBios
KaloBios Pharmaceuticals is a therapeutic antibody company using its proprietary antibody engineering technology, Humaneering™, for the development of a pipeline of antibody therapeutics. Its two most advanced drug candidates are KB002 and KB001. KB002 is designed for the treatment of rheumatoid arthritis, asthma, and other autoimmune diseases. KB001 is designed to treat life-threatening Pseudomonas aeruginosa lung infections, a common problem of cystic fibrosis and mechanically ventilated patients.For more information, please visit www.kalobios.com
Leave a reply
Latest Headlines:
Friday August 31, 2012
Zscaler Secures $38 Million Investment Round
Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.
Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects
Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding
Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies
Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains
Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster
Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility